Publications du service

Principales publications scientifiques du service d'oncologie médicale de l'hôpital Saint Antoine de ces dix dernières années.

  • Lupinacci RM, et al. Pancreatic ductal adenocarcinoma harboring microsatellite instability / DNA mismatch repair deficiency. Towards personalized medicine. Surg Oncol. 2019 Mar;28:121-127.

  • Taieb J, et al. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives.
    Cancer Treat Rev. 2019 May;75:1-11.

  • Argilés G, et al. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Eur J Cancer. 2019 May;112:12-19.

  • Taieb J, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Ann Oncol. 2019 Sep 1;30(9):1466-1471.

  • Toulmonde M, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
    Lancet Oncol. 2019 Sep;20(9):1263-1272

  • Svrcek M, et al. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
    Bull Cancer. 2019 Feb;106(2):119-128.

  • Cohen R, et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
    JAMA Oncol. 2018; 1;5(4):551-555

  • Goey KKH, et al. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.,
    Eur J Cancer, 2018, 100, 35-45

  • Van Cutsem E, et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
    Oncologist, 2018, Sep 6. pii: theoncologist.2018-0072. doi: 10.1634/theoncologist.2018-0072. [Epub ahead of print]

  • Pellat A, et al. Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.,
    Neuroendocrinology, 2018, 107, 24-31

  • Malgras B, et al for RENAPE Network. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.,
    Ann Surg Oncol, 2018, 25, 3271-3279.

  • Bouquot M, et al. Prognostic value and characteristics of N1c colorectal cancer.,
    Colorectal Dis, 2018, 20, O248-O255

  • Cohen R, et al. Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.,
    Bull Cancer, 2018, Feb;106(2):137-142.

  • André T et al.
    Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France phase III trial. Sargent, DJ, André, T, Grothey, A, Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. J Clin Oncol, 2018 (sous presse)

  • Sobrero A, Grothey A, Iveson T, Labianca R, Yoshino T, Taieb J, Maughan T, Buyse M, Andre T, Meyerhardt J, Shields AF, Souglakos I, Douillard JY, Cervantes A. The hard road to data interpretation: three or six months of adjuvant chemotherapy for patients with stage III colon cancer?
    Ann Oncol. 2018 Feb 9. doi: 10.1093/annonc/mdy064. [Epub ahead of print]

  • Mésange P, Bouygues A, Ferrand N, Sabbah M, Escargueil AE, Savina A, Chibaudel B, Tournigand C, Andre T, de Gramont A, Larsen AK.
    Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status. Clin Cancer Res. 2018 Feb 28.

  • Grothey A, Sobrero A, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt J, Vernerey D, Yamanaka T, Boukovinas I, Meyers J, Renfro L, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent D, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018, March 29, 2018 vol. 378 no. 13.

  • Corcoran R, André T, Atreya C, Schellens J, Yoshino T, Bendell J, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients With BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 Feb 5. doi: 10.1158/2159-8290.CD-17-1226. [Epub ahead of print]

  • Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Jan 20:JCO2017769901.

  • Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA & al…and André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol, 2017, 18, 1182-1191.

  • Hickish T et al.MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled,
    phase 3 study
    . Lancet Oncol. 2017 Feb;18(2):192-201.

  • Bachet JB et al. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346.

  • Boeckx N et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017 Apr 25.

  • Cohen R et al. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol. 2017 Feb;18(2):9

  • Pilati C etal. Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. J Pathol. 2017 May;242(1):10-15

  • Sargent DJ et al. Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon Cancer. J Clin Oncol. 2016 Aug 15

  • Papamichael D et al. Adjuvant Colon Cancer Endpoints (ACCENT) GroupValidity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. J Geriatr Oncol. 2016 Nov;7(6):422-429

  • Shah MA et al. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016;34(8):843-53

  • Adenis A et al.. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer. 2016 Jul 7;16:412.

  • Hammel P et al. LAP07 Trial Group. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016 May 3;315(17):1844-53.

  • Cohen R et al. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer. Curr Oncol Rep. 2016 Mar;18(3):18.

  • Cheung WY et al. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10;34(11):1182-9

  • Buhard O et al. HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. J Med Genet. 2016 Jun;53(6):377-84.

  • Shah MA et al. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J Clin Oncol. 2016 Mar 10;34(8):843-53.

  • Lapeyre-Prost A et al. Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. Groupe Coopérateur Multidisciplinaire en Oncologie, the Fédération Francophone de la Cancérologie Digestive, and the UNICANCER Investigators of the PRODIGE Intergroup. Clin Colorectal Cancer. 2016 Sep;15(3):250-6.

  • Hebbar M et al. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Ann Oncol 2015;26:340-7.

  • André T et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol . 2015;33(35):4176-87.

  • Tournigand C et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial). Lancet Oncol . 2015 (15):1493-505

  • Borg C et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study . Ann Oncol 2014;25:2205-10.

  • Peeters M et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16.

  • André Tet al.; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status . Curr Colorectal Cancer Rep. 2013;9:261-269.

  • Bennouna J et al.; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.

  • Shi Q et al. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database . J Clin Oncol. 2013;31(29):3656-63.

  • Kubicka S et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013 (9):2342-9.

  • Chibaudel B et al. Platinum-sensitivity in metastatic colorectal cancer: towards a definition . Eur J Cancer. 2013 49(18):3813-20.

  • André T et al.; GERCOR. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013;24:412-9.

  • Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353-60.

  • de Gramont A et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012;13:1225-33.

  • Sargent DJ et al.; ARCAD Clinical Trials Program. The ARCAD clinical trials program: an update and invitation . Oncologist. 2012;17:188-91.

  • Tournigand C, de Gramont A. Chemotherapy: Is adjuvant chemotherapy an option for stage II colon cancer? Nat Rev Clin Oncol. 2011;8:574-6.

  • Buyse M et al.. The ARCAD advanced colorectal cancer database--open for business; ARCAD Clinical Trials Program . Ann Oncol. 2012;23:281-2.

  • Sargent D et al. Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011;47(7):990-6.

  • Chibaudel B et al. Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy-An Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol. 2011;29:4199-204.

  • Chibaudel B et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study . Oncologist 2011;16:1228-38.

  • de Gramont A et al. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program . J Clin Oncol. 2010;28:527-30.

  • Buyse M et al. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010 (6):309-17.

  • de Gramont A et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol, 2010, 28, 460-5.

  • Chibaudel B et al. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Ann Oncol 2009;20:1383-6.

  • Chibaudel B et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer ? The GERCOR OPTIMOX2 study . J Clin Oncol, 2009, 27, 5727-33.

  • André T et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant tr.eatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009, 27, 3109-16.

  • Sargent D et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872-7.

  • de Gramont A et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007;25:3224-9.

  • André T et al; GERCOR. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007;18:77-81.

  • Goldberg RM et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.

  • Tournigand C et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.

  • Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.

  • André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004 Jun 3;350(23):2343-51.

  • de Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000:2938−47.